Opella reports temporary supply disruption for Bisolvon cough syrup
Opella announced a temporary supply disruption for Bisolvon cough syrup (adult and children's formulations) to Brazil's health regulator (ANVISA) due to a raw material shortage. The company stated the issue does not affect the safety or efficacy of the medications.
Opella, a pharmaceutical company, has notified Brazil's National Health Surveillance Agency (ANVISA) of a temporary disruption in the supply of its Bisolvon cough syrup for both adults and children. The notification was filed on May 28, 2025, citing a shortage of raw materials as the cause.
The affected products are specifically BISOLVON XAROPE ADULTO 8MG/5ML 120ML and BISOLVON XAROPE INFANTIL 4MG/5ML. Opella has emphasized that this supply issue is unrelated to the safety or efficacy of the medications.
The company is reportedly making efforts to resolve the situation and restore product availability as quickly as possible. Patients currently using these medications are advised to consult their physician for guidance on treatment alternatives or continuity.
Further information can be obtained through Opella's customer service channels.